Clinical trials: Ampullary Carcinoma
Biliary Tract Cancer, Gallbladder Cancer
Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers
The purpose of this study is to determine whether fit patients (with ECOG performance score of 0-1) with advanced biliary tract cancer (ABC) benefit from chemotherapy in the second-line setting (after prior therapy with cisplatin…
- Conditions
- Biliary Tract Cancer, Gallbladder Cancer, Cholangiocarcinoma, Ampullary Cancer
- Trial name
- ABC06 (NCT01926236)
- Testing
- Active Symptom Control, L-folinic acid, 5 FU
- Where
- 17 sites in United Kingdom
- Volunteers
- 162 people
- Sponsor
- The Christie NHS Foundation Trust
Colorectal Cancer, Esophagus Cancer
Individualized Dose Escalation of 5-FU for Gastrointestinal Cancer
This is a single-arm clinical trial to evaluate the feasibility of a chemotherapy regimen using adaptive, individualized dose escalation of 5-FU chemotherapy for patients who have good tolerance of the initial dose.
- Conditions
- Colorectal Cancer, Esophagus Cancer, Appendix Cancer, Small Bowel Cancer
- Trial name
- NCT05780684
- Testing
- FOX dose-escalation algorithm
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Ampullary Carcinoma
Surufatinib Combined With Toripalimab and AG Regiments for First-line Treatment of Unresectable or Relapsing Metastatic Ampullary Carcinoma
A Phase Ⅱ, single-arm study to assess the safety, tolerability, and efficacy of Surufatinib Combination With Toripalimab in Patients With recurrent or metastatic ampulla tumors.
- Trial name
- NCT06062485
- Testing
- Surufatinib+Toripalimab+AG
- Volunteers
- 30 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Gastric Cancer, Colorectal Cancer
A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer
This study is to define the safety profile and to determine the Maximal tolerated dose regimen and preliminary efficacy of AbGn-107 administered every 14 days (Q2W regimen) or 28 days (Q4W regimen) in patients with…
- Conditions
- Gastric Cancer, Colorectal Cancer, Pancreatic Cancer, Biliary Cancer
- Trial name
- NCT02908451
- Testing
- AbGn-107
- Where
- 9 sites in United States, Taiwan
- Volunteers
- 39 people
- Sponsor
- AbGenomics B.V Taiwan Branch
Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma
Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI
The goal of this open-label randomized, multicenter, comparative phase II trial is to evaluate the efficacy of the immunotherapy, dostarlimab, as first-line treatment for deficient mismatch repair (dMMR)/microsatellite…
- Conditions
- Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma, Adrenocortical Carcinoma, Neuroendocrine Carcinoma
- Trial name
- Pan-MSI-ACSE (NCT06333314)
- Testing
- Dostarlimab, Chemotherapy
- Where
- 22 sites in France
- Volunteers
- 120 people
- Sponsor
- UNICANCER